Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $20.2M | $49.6M | $110M | $164M | $203M | $292M |
| Revenue growth | — | 146.0% | 122.3% | 48.7% | 23.9% | 43.7% |
| Operating income | -$83.5M | -$115M | -$81.9M | -$44.0M | -$33.6M | $24.9M |
| Operating margin | -414.5% | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% |
| Net income | -$91.1M | -$123M | -$94.7M | -$62.3M | -$54.8M | $554K |
| Net margin | -452.2% | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
| EPS (diluted) | -$2.14 | -$1.55 | -$0.70 | -$0.45 | -$0.37 | $0.00 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$80.6M | -$95.5M | -$103M | -$47.0M | -$37.0M | $28.6M |
| Capital expenditures | $377K | $1.08M | — | — | — | — |
| Free cash flow | -$80.9M | -$96.6M | — | — | — | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $37.6M | $67.3M | $122M | $67.4M | $71.6M | $111M |
| Total assets | $159M | $304M | $345M | $323M | $323M | $384M |
| Total liabilities | $125M | $209M | $299M | $329M | $353M | $370M |
| Long-term debt | $87.0M | $88.1M | $187M | $191M | $217M | $220M |
| Shareholders' equity | $33.8M | $95.2M | $45.2M | -$6.78M | -$29.6M | $13.7M |
| Retained earnings | -$337M | -$460M | -$555M | -$617M | -$672M | -$671M |
| Shares (wtd avg diluted) | — | 79.0M | 136M | 138M | 147M | 173M |
Every figure is extracted from Xeris Biopharma Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.